瘤免疫动力学和IIIA期NSCLC患者的长期临床结果,这些患者接受了新辅助化学免疫治疗
Dominic Schmid1,2, Bettina Sobottka3, Massimiliano Manzo4
1Laboratory of Cancer Immunology, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland. dominic.schmid@unibas.ch.
Nature communications
|September 30, 2025
概括
新辅助化疗免疫疗法对可切除非小细胞肺癌 (NSCLC) 的长期生存有好处. 像T细胞定位和TCR多样性等生物标志物可以预测患者对治疗的反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 新辅助化疗免疫疗法是可切除非小细胞肺癌 (NSCLC) 的有希望的治疗方法.
- 确定治疗反应的可靠生物标志物仍然是一个挑战.
研究的目的:
- 评估新辅助化疗和抗PD-L1抑制在IIIA期NSCLC的长期临床结果.
- 描述针对个性化治疗策略的抗瘤免疫反应.
主要方法:
- 来自SAKK 16/14试验的二次结果分析.
- 瘤免疫细胞透的计算机辅助空间图像分析.
- 瘤组织的基因组分析.
- 循环免疫细胞的流动细胞计.
主要成果:
- 平均无事件生存 (EFS) 为4.0年;平均随访5.4年后没有达到总生存.
- CD8+ T细胞瘤定位和三级淋巴体结构与改善的EFS相关.
- 内TCR多样性与治疗反应有关.
- 循环中的CD39+ PD-1+ CD8+ T细胞和升高的CCL15水平表明持续的益处.
结论:
- 新辅助化学免疫疗法在可切除IIIA期NSCLC中提供了持久的临床益处.
- 瘤免疫微环境特征和特定的循环生物标志物可以预测治疗反应.
- 这些发现支持基于生物标志物的新辅助治疗NSCLC的个性化.
相关概念视频
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


